Enter inventor name

Wendelin Frick

This inventor holds 49 USPTO granted patents and 3 published patent applications and 12 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Sanofi-A Ventis Deutschland Gmbh, Aventis Pharma Deutschland, Gmbh, Hoechst Aktiengesellschaft. Active years: 1997-2013.

USPTO Granted Patents = 49 (Patent Applications = 3)

% Patents Active = 63.3

EPO Patents = 12 (Patent Applications = 2)

Average Co-Inventor Count = 5.2

ph-index = 16

Forward Citations = 855(Granted Patents)

Location History:

Frankfur am Main, DE (1997)
Huenstetten-Beuerbach, DE (1999 - 2010)
Hünstetten-Beuerbach, DE (2001 - 2010)
Hunstetten-Beuerbach, DE (2007 - 2012)
Frankfurt-am-Main, DE (2009 - 2013)

Company Filing History:

30 out of 1,855

Sanofi-A Ventis Deutschland Gmbh

patents

16 out of 330

Aventis Pharma Deutschland, Gmbh

patents

2 out of 6,705

Hoechst Aktiengesellschaft

Years Active: 1997-2013

Loading Chart...

Areas of Expertise:

1,4-Benzothiepin Derivatives

Diphenylazetidinones

Cholesterol Binding Proteins

Pharmaceuticals

Medicaments

Drug Development

Aryl-Substituted Compounds

Fluorine Substituted Derivatives

Hypolipidaemic Agents

Glycosylphosphatidylinositol

Phosophoinositoglycan

Therapeutic Compounds

49 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8461312 - Method for the production of 1,4-benzothiepin-1,1-dioxide derivatives (2013-06-11),

2. 8106023 - 1,4-benzothiepin-1, 1-dioxide derivatives with improved properties method for producing the same, drugs containing said compounds and the use thereof (2012-01-31),

3. 8101583 - 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with fluorine, method for producing the same, drugs containing said compounds and use thereof (2012-01-24),

4. 8017350 - Glimepiride- and insulin-induced glycosylphosphatidylinositol-specific phospholipase C regulation (2011-09-13),

5. 7956085 - 1,4-benzothiepine 1,1-dioxide derivatives substituted by benzyl radicals, method for their preparation, pharmaceuticals comprising these compounds, and the use thereof (2011-06-07),

6. 7923468 - 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with cyclohexyl groups, method for producing the same, drugs containing said compounds and use thereof (2011-04-12),

7. 7786103 - Method for isolating an intestinal cholesterol binding protein (2010-08-31),

8. 7772429 - Diphenylazetidinone with improved physiological properties, process for its preparation, medicaments comprising this compound, and its use (2010-08-10),

9. 7674773 - Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use (2010-03-09),

10. 7671047 - Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use (2010-03-02),

11. 7666848 - Thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof (2010-02-23),

12. 7615536 - 1,4-benzothiazepine 1,1-dioxide derivative, process for its preparation, medicaments comprising this compound, and use thereof as a hypolipidaemic (2009-11-10),

13. 7579339 - Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use (2009-08-25),

14. 7576200 - Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use (2009-08-18),

15. 7563888 - Process for the preparation of diphenyl azetidinone derivatives (2009-07-21),

Title: The Innovative Journey of Wendelin Frick

Introduction: Wendelin Frick, a notable inventor based in Hünstetten-Beuerbach, Germany, has made significant contributions to the field of pharmaceuticals and organic chemistry. With an impressive portfolio of 48 patents, Frick has been at the forefront of developing innovative methods for producing complex chemical compounds that have potential therapeutic applications.

Latest Patents: Among his most recent inventions is the "Method for the production of 1,4-benzothiepin-1,1-dioxide derivatives." This patent focuses on an efficient process for creating 1,4-benzothiepin-1,1-dioxide derivatives that are substituted with benzyl groups, showcasing Frick's dedication to enhancing chemical production methods. Another notable patent is titled "1,4-benzothiepin-1,1-dioxide derivatives with improved properties, method for producing the same, drugs containing said compounds and the use thereof." This invention introduces novel derivatives with improved properties and outlines their applications in pharmaceuticals, indicating Frick's commitment to improving drug efficacy.

Career Highlights: Wendelin Frick has had a prominent career, notably working with reputable companies such as Sanofi-Aventis Deutschland GmbH and Aventis Pharma Deutschland GmbH. His extensive experience in these organizations has allowed him to refine his skills and contribute to numerous projects focused on innovative drug development.

Collaborations: Throughout his career, Frick has collaborated with esteemed colleagues, including Heiner Glombik and Hubert Heuer. These partnerships have fostered a collaborative environment that encourages the exchange of ideas, ultimately leading to groundbreaking advancements in pharmaceutical technologies.

Conclusion: Wendelin Frick's impressive patent portfolio and his contributions to innovative methodologies in the field of organic chemistry highlight his significance as an inventor. His work not only advances scientific knowledge but also has the potential to impact the pharmaceutical industry significantly, paving the way for new therapeutic options.

Profile summary based on public USPTO records.

Please report any incorrect information to [email protected]